{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T02:01:09Z","timestamp":1784253669849,"version":"3.55.0"},"publisher-location":"New York, NY","reference-count":48,"publisher":"Springer US","isbn-type":[{"value":"9781071636619","type":"print"},{"value":"9781071636626","type":"electronic"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1007\/978-1-0716-3662-6_31","type":"book-chapter","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T06:03:10Z","timestamp":1709272990000},"page":"457-475","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Promises of Lipid-Based Nanocarriers for Delivery of Dimethyl Fumarate to Multiple Sclerosis Brain"],"prefix":"10.1007","author":[{"given":"Sreya","family":"Subhash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishtha","family":"Chaurawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaisar","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,2]]},"reference":[{"key":"31_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/ENE.12883","volume":"23 Suppl 1","author":"O Torkildsen","year":"2016","unstructured":"Torkildsen O, Myhr KM, B\u00f8 L (2016) Disease-modifying treatments for multiple sclerosis - a review of approved medications. Eur J Neurol 23 Suppl 1:18\u201327. https:\/\/doi.org\/10.1111\/ENE.12883","journal-title":"Eur J Neurol"},{"key":"31_CR2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/135245859700300213","volume":"3","author":"H Lassmann","year":"1997","unstructured":"Lassmann H, Br\u00fcck W, Lucchinetti C, Rodriguez M (1997) Remyelination in multiple sclerosis. Mult Scler 3:133\u2013136. https:\/\/doi.org\/10.1177\/135245859700300213","journal-title":"Mult Scler"},{"key":"31_CR3","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ijpharm.2016.10.024","volume":"515","author":"P Kumar","year":"2016","unstructured":"Kumar P, Sharma G, Kumar R et al (2016) Promises of a biocompatible nanocarrier in improved brain delivery of quercetin: biochemical, pharmacokinetic and biodistribution evidences. Int J Pharm 515:307\u2013314. https:\/\/doi.org\/10.1016\/j.ijpharm.2016.10.024","journal-title":"Int J Pharm"},{"key":"31_CR4","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.arcmed.2014.11.013","volume":"45","author":"GG Ortiz","year":"2014","unstructured":"Ortiz GG, Pacheco-Mois\u00e9s FP, Mac\u00edas-Islas M\u00c1 et al (2014) Role of the blood-brain barrier in multiple sclerosis. Arch Med Res 45:687\u2013697. https:\/\/doi.org\/10.1016\/j.arcmed.2014.11.013","journal-title":"Arch Med Res"},{"key":"31_CR5","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2147\/DDDT.S50962","volume":"8","author":"JA Nicholas","year":"2014","unstructured":"Nicholas JA, Lee Boster A, Imitola J et al (2014) Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate. Drug Des Devel Ther 8:897\u2013908. https:\/\/doi.org\/10.2147\/DDDT.S50962","journal-title":"Drug Des Devel Ther"},{"key":"31_CR6","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/J.1610-0387.2012.07996.X","volume":"10","author":"M Meissner","year":"2012","unstructured":"Meissner M, Valesky EM, Kippenberger S, Kaufmann R (2012) Dimethyl fumarate - only an anti-psoriatic medication? J Dtsch Dermatol Ges 10:793\u2013801. https:\/\/doi.org\/10.1111\/J.1610-0387.2012.07996.X","journal-title":"J Dtsch Dermatol Ges"},{"key":"31_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/S12551-016-0244-4","volume":"9","author":"P Deshmukh","year":"2017","unstructured":"Deshmukh P, Unni S, Krishnappa G, Padmanabhan B (2017) The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys Rev 9:41\u201356. https:\/\/doi.org\/10.1007\/S12551-016-0244-4","journal-title":"Biophys Rev"},{"key":"31_CR8","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1021\/ACSCHEMNEURO.6B00428","volume":"8","author":"P Kumar","year":"2017","unstructured":"Kumar P, Sharma G, Kumar R et al (2017) Enhanced brain delivery of dimethyl fumarate employing tocopherol-acetate-based nanolipidic carriers: evidence from pharmacokinetic, biodistribution, and cellular uptake studies. ACS Chem Neurosci 8:860\u2013865. https:\/\/doi.org\/10.1021\/ACSCHEMNEURO.6B00428","journal-title":"ACS Chem Neurosci"},{"key":"31_CR9","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.2217\/nnm-2017-0082","volume":"12","author":"P Kumar","year":"2017","unstructured":"Kumar P, Sharma G, Kumar R et al (2017) Stearic acid based, systematically designed oral lipid nanoparticles for enhanced brain delivery of dimethyl fumarate. Nanomedicine 12:2607\u20132621. https:\/\/doi.org\/10.2217\/nnm-2017-0082","journal-title":"Nanomedicine"},{"key":"31_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.toxlet.2007.01.010","volume":"169","author":"N Franco-Pons","year":"2007","unstructured":"Franco-Pons N, Torrente M, Colomina MT, Vilella E (2007) Behavioral deficits in the cuprizone-induced murine model of demyelination\/remyelination. Toxicol Lett 169:205\u2013213. https:\/\/doi.org\/10.1016\/j.toxlet.2007.01.010","journal-title":"Toxicol Lett"},{"key":"31_CR11","unstructured":"Brain targeting drug delivery systems for the management of brain disorders: molecular targets and nanotechnological strategies - Google Search"},{"key":"31_CR12","doi-asserted-by":"publisher","unstructured":"Dighriri IM, Aldalbahi AA, Albeladi F et al (2023) An overview of the history, pathophysiology, and pharmacological interventions of multiple sclerosis. Cureus 15. https:\/\/doi.org\/10.7759\/CUREUS.33242","DOI":"10.7759\/CUREUS.33242"},{"key":"31_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/FNENG.2013.00007\/ABSTRACT","volume":"6","author":"AD Wong","year":"2013","unstructured":"Wong AD, Ye M, Levy AF et al (2013) The blood-brain barrier: an engineering perspective. Front Neuroeng 6:7. https:\/\/doi.org\/10.3389\/FNENG.2013.00007\/ABSTRACT","journal-title":"Front Neuroeng"},{"key":"31_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1136\/JNNP-2017-316011","volume":"89","author":"JI Spencer","year":"2018","unstructured":"Spencer JI, Bell JS, DeLuca GC (2018) Vascular pathology in multiple sclerosis: reframing pathogenesis around the blood-brain barrier. J Neurol Neurosurg Psychiatry 89:42\u201352. https:\/\/doi.org\/10.1136\/JNNP-2017-316011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"31_CR15","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/J.CELL.2023.03.008","volume":"186","author":"M Charabati","year":"2023","unstructured":"Charabati M, Wheeler MA, Weiner HL, Quintana FJ (2023) Multiple sclerosis: neuroimmune crosstalk and therapeutic targeting. Cell 186:1309\u20131327. https:\/\/doi.org\/10.1016\/J.CELL.2023.03.008","journal-title":"Cell"},{"key":"31_CR16","doi-asserted-by":"publisher","unstructured":"Merjane J, Chung R, Patani R, Lisowski L (2023) Molecular mechanisms of amyotrophic lateral sclerosis as broad therapeutic targets for gene therapy applications utilizing adeno-associated viral vectors. Med Res Rev. https:\/\/doi.org\/10.1002\/MED.21937","DOI":"10.1002\/MED.21937"},{"key":"31_CR17","doi-asserted-by":"publisher","unstructured":"de S\u00e8ze J, Maillart E, Gueguen A et al (2023) Anti-CD20 therapies in multiple sclerosis: from pathology to the clinic. Front Immunol 14. https:\/\/doi.org\/10.3389\/FIMMU.2023.1004795","DOI":"10.3389\/FIMMU.2023.1004795"},{"key":"31_CR18","doi-asserted-by":"publisher","unstructured":"Graham EL (2023) Neuroimmunological disorders: the gender effect. Neurol Clin 41. https:\/\/doi.org\/10.1016\/J.NCL.2022.10.004","DOI":"10.1016\/J.NCL.2022.10.004"},{"key":"31_CR19","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nrneurol.2012.168","volume":"8","author":"H Lassmann","year":"2012","unstructured":"Lassmann H, Van Horssen J, Mahad D (2012) Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 8:647\u2013656. https:\/\/doi.org\/10.1038\/nrneurol.2012.168","journal-title":"Nat Rev Neurol"},{"key":"31_CR20","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.neurol.2018.03.006","volume":"174","author":"H Z\u00e9phir","year":"2018","unstructured":"Z\u00e9phir H (2018) Progress in understanding the pathophysiology of multiple sclerosis. Rev Neurol (Paris) 174:358\u2013363. https:\/\/doi.org\/10.1016\/j.neurol.2018.03.006","journal-title":"Rev Neurol (Paris)"},{"key":"31_CR21","doi-asserted-by":"publisher","first-page":"8370","DOI":"10.3390\/IJMS22168370","volume":"22","author":"R Balasa","year":"2021","unstructured":"Balasa R, Barcutean L, Mosora O, Manu D (2021) Reviewing the significance of blood\u2013brain barrier disruption in multiple sclerosis pathology and treatment. Int J Mol Sci 22:8370. https:\/\/doi.org\/10.3390\/IJMS22168370","journal-title":"Int J Mol Sci"},{"key":"31_CR22","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1212\/CON.0000000000001136","volume":"28","author":"MD Goldman","year":"2022","unstructured":"Goldman MD, Ward M, Goldman MD (2022) Epidemiology and pathophysiology of multiple sclerosis. Contin Lifelong Learn Neurol 28:988\u20131005. https:\/\/doi.org\/10.1212\/CON.0000000000001136","journal-title":"Contin Lifelong Learn Neurol"},{"key":"31_CR23","first-page":"988","volume":"28","author":"M Ward","year":"2022","unstructured":"Ward M, Goldman MD (2022) Epidemiology and pathophysiology of multiple sclerosis. Continuum (Minneap Minn) 28:988\u20131005. 1 - Google Search","journal-title":"Continuum (Minneap Minn)"},{"key":"31_CR24","doi-asserted-by":"publisher","unstructured":"Maier S, Barcutean L, Andone S et al (2023) Recent progress in the identification of early transition biomarkers from relapsing-remitting to progressive multiple sclerosis. Int J Mol Sci 24. https:\/\/doi.org\/10.3390\/IJMS24054375","DOI":"10.3390\/IJMS24054375"},{"key":"31_CR25","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/S40263-022-00965-7","volume":"36","author":"L Freeman","year":"2022","unstructured":"Freeman L, Longbrake EE, Coyle PK et al (2022) High-efficacy therapies for treatment-Na\u00efve individuals with relapsing-remitting multiple sclerosis. CNS Drugs 36:1285\u20131299. https:\/\/doi.org\/10.1007\/S40263-022-00965-7","journal-title":"CNS Drugs"},{"key":"31_CR26","doi-asserted-by":"publisher","unstructured":"Ransohoff RM (2023) Multiple sclerosis: role of meningeal lymphoid aggregates in progression independent of relapse activity. Trends Immunol 44. https:\/\/doi.org\/10.1016\/J.IT.2023.02.002","DOI":"10.1016\/J.IT.2023.02.002"},{"key":"31_CR27","doi-asserted-by":"publisher","unstructured":"Gilli F, Ceccarelli A (2023) Magnetic resonance imaging approaches for studying mouse models of multiple sclerosis: a mini review. J Neurosci Res. https:\/\/doi.org\/10.1002\/JNR.25193","DOI":"10.1002\/JNR.25193"},{"key":"31_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/J.NEUROL.2015.10.006","volume":"172","author":"E Leray","year":"2016","unstructured":"Leray E, Moreau T, Fromont A, Edan G (2016) Epidemiology of multiple sclerosis. Rev Neurol (Paris) 172:3\u201313. https:\/\/doi.org\/10.1016\/J.NEUROL.2015.10.006","journal-title":"Rev Neurol (Paris)"},{"key":"31_CR29","doi-asserted-by":"publisher","unstructured":"Pilotto S, Zoledziewska M, Fenu G et al (2023) Disease-modifying therapy for multiple sclerosis: implications for gut microbiota. Mult Scler Relat Disord 73. https:\/\/doi.org\/10.1016\/J.MSARD.2023.104671","DOI":"10.1016\/J.MSARD.2023.104671"},{"key":"31_CR30","doi-asserted-by":"publisher","unstructured":"El Ouaamari Y, Van den Bos J, Willekens B et al (2023) Neurotrophic factors as regenerative therapy for neurodegenerative diseases: current status, challenges and future perspectives. Int J Mol Sci 24. https:\/\/doi.org\/10.3390\/IJMS24043866","DOI":"10.3390\/IJMS24043866"},{"key":"31_CR31","doi-asserted-by":"publisher","unstructured":"Furman MJ, Meuth SG, Albrecht P et al (2023) B cell targeted therapies in inflammatory autoimmune disease of the central nervous system. Front Immunol 14. https:\/\/doi.org\/10.3389\/FIMMU.2023.1129906","DOI":"10.3389\/FIMMU.2023.1129906"},{"key":"31_CR32","doi-asserted-by":"publisher","first-page":"190","DOI":"10.2174\/1872214811004030190","volume":"4","author":"C Spuch","year":"2012","unstructured":"Spuch C, Navarro C (2012) Transport mechanisms at the blood-cerebrospinal-fluid barrier: role of megalin (LRP2). Recent Pat Endocr Metab Immune Drug Discov 4:190\u2013205. https:\/\/doi.org\/10.2174\/1872214811004030190","journal-title":"Recent Pat Endocr Metab Immune Drug Discov"},{"key":"31_CR33","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3174\/AJNR.A7398","volume":"43","author":"SC Kolbe","year":"2022","unstructured":"Kolbe SC, Garcia LM, Yu N et al (2022) Lesion volume in relapsing multiple sclerosis is associated with perivascular space enlargement at the level of the basal ganglia. AJNR Am J Neuroradiol 43:238\u2013244. https:\/\/doi.org\/10.3174\/AJNR.A7398","journal-title":"AJNR Am J Neuroradiol"},{"key":"31_CR34","doi-asserted-by":"publisher","unstructured":"Ndemazie NB, Inkoom A, Morfaw EF et al (2022) Multi-disciplinary approach for drug and gene delivery systems to the brain. AAPS PharmSciTech 23. https:\/\/doi.org\/10.1208\/s12249-021-02144-1","DOI":"10.1208\/s12249-021-02144-1"},{"key":"31_CR35","doi-asserted-by":"publisher","unstructured":"Hern\u00e1ndez-Pedro NY, Espinosa-Ramirez G, De La Cruz VP et al (2013) Initial immunopathogenesis of multiple sclerosis: innate immune response. Clin Dev Immunol 2013. https:\/\/doi.org\/10.1155\/2013\/413465","DOI":"10.1155\/2013\/413465"},{"key":"31_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/238428","volume":"2013","author":"M Masserini","year":"2013","unstructured":"Masserini M (2013) Nanoparticles for brain drug delivery. ISRN Biochem 2013:1\u201318. https:\/\/doi.org\/10.1155\/2013\/238428","journal-title":"ISRN Biochem"},{"key":"31_CR37","doi-asserted-by":"publisher","unstructured":"Upadhyay RK (2014) Drug delivery systems, CNS protection, and the blood brain barrier. Biomed Res Int 2014. https:\/\/doi.org\/10.1155\/2014\/869269","DOI":"10.1155\/2014\/869269"},{"key":"31_CR38","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/J.ARCMED.2014.11.013","volume":"45","author":"GG Ortiz","year":"2014","unstructured":"Ortiz GG, Pacheco-Mois\u00e9s FP, Mac\u00edas-Islas M\u00c1 et al (2014) Role of the blood\u2013brain barrier in multiple sclerosis. Arch Med Res 45:687\u2013697. https:\/\/doi.org\/10.1016\/J.ARCMED.2014.11.013","journal-title":"Arch Med Res"},{"key":"31_CR39","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/1061186X.2019.1630415","volume":"28","author":"SA Pena","year":"2020","unstructured":"Pena SA, Iyengar R, Eshraghi RS et al (2020) Gene therapy for neurological disorders: challenges and recent advancements. J Drug Target 28:111\u2013128. https:\/\/doi.org\/10.1080\/1061186X.2019.1630415","journal-title":"J Drug Target"},{"key":"31_CR40","doi-asserted-by":"publisher","unstructured":"Teixeira MI, Lopes CM, Amaral MH, Costa PC (2023) Surface-modified lipid nanocarriers for crossing the blood-brain barrier (BBB): a current overview of active targeting in brain diseases. Colloids Surf B Biointerfaces 221. https:\/\/doi.org\/10.1016\/J.COLSURFB.2022.112999","DOI":"10.1016\/J.COLSURFB.2022.112999"},{"key":"31_CR41","doi-asserted-by":"publisher","unstructured":"Kumar P, Sharma G, Kumar R et al (2017) Vitamin-derived nanolipoidal carriers for brain delivery of dimethyl fumarate: a novel approach with preclinical evidence. ACS Chem Neurosci. acschemneuro.7b00041. https:\/\/doi.org\/10.1021\/acschemneuro.7b00041","DOI":"10.1021\/acschemneuro.7b00041"},{"key":"31_CR42","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1021\/acschemneuro.6b00428","volume":"8","author":"P Kumar","year":"2017","unstructured":"Kumar P, Sharma G, Kumar R et al (2017) Enhanced brain delivery of dimethyl fumarate employing tocopherol-acetate-based nanolipidic carriers: evidence from pharmacokinetic, biodistribution, and cellular uptake studies. ACS Chem Neurosci 8:860\u2013865. https:\/\/doi.org\/10.1021\/acschemneuro.6b00428","journal-title":"ACS Chem Neurosci"},{"key":"31_CR43","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.2217\/NNM-2017-0082","volume":"12","author":"P Kumar","year":"2017","unstructured":"Kumar P, Sharma G, Kumar R et al (2017) Stearic acid based, systematically designed oral lipid nanoparticles for enhanced brain delivery of dimethyl fumarate. Nanomedicine (Lond) 12:2607\u20132621. https:\/\/doi.org\/10.2217\/NNM-2017-0082","journal-title":"Nanomedicine (Lond)"},{"key":"31_CR44","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1208\/s12249-019-1296-0","volume":"20","author":"P Kumar","year":"2019","unstructured":"Kumar P, Sharma G, Gupta V et al (2019) Oral delivery of methylthioadenosine to the brain employing solid lipid nanoparticles: pharmacokinetic, behavioral, and histopathological evidences. AAPS PharmSciTech 20:74. https:\/\/doi.org\/10.1208\/s12249-019-1296-0","journal-title":"AAPS PharmSciTech"},{"key":"31_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJPHARM.2022.122084","volume":"625","author":"S Mehdi-alamdarlou","year":"2022","unstructured":"Mehdi-alamdarlou S, Ahmadi F, Azadi A et al (2022) A cell-mimicking platelet-based drug delivery system as a potential carrier of dimethyl fumarate for multiple sclerosis. Int J Pharm 625:122084. https:\/\/doi.org\/10.1016\/J.IJPHARM.2022.122084","journal-title":"Int J Pharm"},{"key":"31_CR46","doi-asserted-by":"publisher","first-page":"225","DOI":"10.15171\/APB.2018.027","volume":"8","author":"S Ojha","year":"2018","unstructured":"Ojha S, Kumar B (2018) Preparation and statistical modeling of solid lipid nanoparticles of dimethyl fumarate for better management of multiple sclerosis. Adv Pharm Bull 8:225\u2013233. https:\/\/doi.org\/10.15171\/APB.2018.027","journal-title":"Adv Pharm Bull"},{"key":"31_CR47","doi-asserted-by":"publisher","unstructured":"Sinha S, Garg V, Sonali, et al (2021) Chitosan-alginate core-shell-corona shaped nanoparticles of dimethyl fumarate in orodispersible film to improve bioavailability in treatment of multiple sclerosis: preparation, characterization and biodistribution in rats. J Drug Deliv Sci Technol 64:. https:\/\/doi.org\/10.1016\/j.jddst.2021.102645","DOI":"10.1016\/j.jddst.2021.102645"},{"key":"31_CR48","unstructured":"clinical trials - Google Search"}],"container-title":["Methods in Molecular Biology","Neuroprotection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-3662-6_31","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T06:24:17Z","timestamp":1709274257000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-3662-6_31"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9781071636619","9781071636626"],"references-count":48,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-3662-6_31","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"2 March 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}